WGU D027
WGU D027 OA Exam Advanced Pathopharmacological
Foundations 200 Tested Questions (Latest ) and
Verified Rationalized Answers, 100% Guarantee Pass
Domain 1: Foundations of Pathophysiology & Cellular Function
Q1: A patient with chronic GERD develops Barrett's esophagus, where the normal squamous
epithelium is replaced by columnar epithelium with goblet cells. This cellular change is best
described as: A) Dysplasia
B) Hyperplasia
C) Metaplasia
D) Anaplasia
Answer: C) Metaplasia
Rationale: Metaplasia is the reversible replacement of one differentiated cell type with another in
response to chronic irritation, which is a protective mechanism. Barrett's esophagus is a classic
example of this adaptation.
Q2: A patient with chronic hypertension develops left ventricular wall thickening without an increase
in chamber size. This adaptation is best described as:
A) Hyperplasia
B) Hypertrophy
C) Atrophy
D) Metaplasia
Answer: B) Hypertrophy
Rationale: Hypertrophy is an increase in cell size, leading to an increase in tissue mass. Cardiac
myocytes are permanent cells that cannot divide, so they respond to increased workload (pressure
overload) by increasing in size.
Q3: A patient with a BRCA1 gene mutation has a significantly increased risk for breast and ovarian
cancer. This mutation affects a gene that is primarily responsible for:
A) Regulating cell cycle checkpoints and DNA repair
B) Controlling growth factor receptor signaling
C) Promoting apoptosis in damaged cells
D) Enhancing cell adhesion
Answer: A) Regulating cell cycle checkpoints and DNA repair
Rationale: BRCA1 and BRCA2 are tumor suppressor genes that produce proteins involved in
repairing damaged DNA. When these genes are mutated, DNA damage can accumulate, leading to
an increased risk of cancer.
Q4: Reperfusion injury following a myocardial infarction is primarily caused by: A)
A complete lack of oxygen delivery to the cardiac tissue.
B) Oxidative stress from the generation of reactive oxygen species (ROS) upon oxygen
reintroduction.
C) Mechanical damage from the pressure of reperfusion.
D) Activation of the complement system only.
, WGU D027
Answer: B) Oxidative stress from the generation of reactive oxygen species (ROS) upon oxygen
reintroduction.
Rationale: When oxygen is reintroduced to ischemic tissue, it triggers a massive generation of ROS,
which cause further cellular damage beyond the initial ischemic insult.
Q5: A patient with sickle cell trait goes on a high-altitude mountain climb and develops a splenic
infarction. The underlying mechanism is:
A) Increased oxygen saturation causing increased RBC proliferation.
B) Decreased oxygen tension causing hemoglobin S to polymerize, leading to RBC sickling.
C) Increased carbon dioxide leading to respiratory alkalosis.
D) Decreased blood viscosity causing vascular stasis.
Answer: B) Decreased oxygen tension causing hemoglobin S to polymerize, leading to RBC sickling.
Rationale: Hypoxia at high altitude causes deoxygenation of hemoglobin S, leading to polymerization
and sickling of red blood cells. These rigid, sickled cells cause vaso-occlusion and infarction.
Q6: A patient with chronic alcoholism develops hepatic steatosis (fatty liver). The primary
mechanism involves:
A) Increased fatty acid oxidation in hepatocytes.
B) Decreased lipoprotein synthesis and export, and increased lipogenesis.
C) Decreased caloric intake leading to protein malnutrition.
D) Increased bile acid synthesis.
Answer: B) Decreased lipoprotein synthesis and export, and increased lipogenesis.
Rationale: Alcohol metabolism generates excess NADH, which promotes lipogenesis and inhibits
fatty acid oxidation. It also impairs apolipoprotein synthesis, reducing VLDL export and leading to fat
accumulation.
Domain 2: Pharmacology Foundations
Q7: A patient is prescribed a drug that undergoes significant first-pass metabolism. To ensure
adequate bioavailability, the prescriber should: A) Administer the drug intravenously.
B) Increase the oral dose.
C) Administer the drug with food.
D) Use a topical formulation.
Answer: A) Administer the drug intravenously.
Rationale: The first-pass effect is the metabolism of a drug by the liver before it reaches systemic
circulation. Administering the drug intravenously bypasses the first-pass effect, delivering 100% of
the drug to the systemic circulation.
Q8: A patient is started on a medication that inhibits the CYP3A4 enzyme system. This will most likely
result in:
A) Decreased levels of drugs metabolized by CYP3A4.
B) Increased levels of drugs metabolized by CYP3A4.
C) No change in levels of drugs metabolized by CYP3A4.
D) Increased renal excretion of drugs metabolized by CYP3A4.
Answer: B) Increased levels of drugs metabolized by CYP3A4.
, WGU D027
Rationale: CYP450 enzymes are responsible for metabolizing many drugs. If a drug inhibits CYP3A4, it
will slow the metabolism of other drugs that are substrates for this enzyme, leading to increased
serum levels and a higher risk of toxicity.
Q9: A patient with a genetic variant in CYP2D6 is prescribed codeine for pain. The patient reports no
relief. This is most likely due to the patient being a: A) Poor metabolizer of codeine.
B) Rapid metabolizer of codeine.
C) Poor metabolizer of morphine.
D) Rapid metabolizer of morphine.
Answer: A) Poor metabolizer of codeine.
Rationale: Codeine is a prodrug that requires metabolism by the CYP2D6 enzyme into its active form,
morphine. A patient who is a poor metabolizer will not convert codeine effectively, resulting in
minimal analgesic effect.
Q10: Which of the following is the best measure of a drug's safety margin?
A) Potency
B) Efficacy
C) Therapeutic Index
D) Half-life
Answer: C) Therapeutic Index
Rationale: The therapeutic index (TI) is the ratio of the toxic dose to the therapeutic dose
(TD50/ED50). A high TI indicates a wide margin of safety, while a low TI indicates a narrow margin
where the drug can easily become toxic.
Q11: A patient is prescribed a drug that acts as a full agonist at the mu-opioid receptor. This means
the drug:
A) Binds to the receptor and produces a maximal response.
B) Binds to the receptor and produces a minimal response.
C) Binds to the receptor and blocks the response.
D) Binds to a different receptor entirely.
Answer: A) Binds to the receptor and produces a maximal response.
Rationale: An agonist is a drug that binds to a receptor and activates it. A full agonist produces a
maximal response, while a partial agonist produces a submaximal response. An antagonist blocks the
receptor without activating it.
Q12: The Beers Criteria is primarily used in clinical practice to: A)
Identify drugs that are safe for use in pregnant women.
B) Identify potentially inappropriate medications for older adults.
C) Determine the correct dosage for pediatric patients.
D) Monitor for drug interactions in patients with renal failure.
Answer: B) Identify potentially inappropriate medications for older adults.
Rationale: The Beers Criteria are a list of medications that are generally considered potentially
inappropriate for use in older adults due to a high risk of adverse effects or a lack of efficacy.
, WGU D027
Domain 3: Cardiovascular & Respiratory Systems
Q13: A 68-year-old patient with a history of severe asthma and chronic heart failure requires
treatment for tachycardia. Which classification of cardiovascular drug is strictly contraindicated in
this patient?
A) Cardioselective Beta-1 Blockers
B) Non-selective Beta Blockers
C) Angiotensin-Converting Enzyme (ACE) Inhibitors
D) Loop Diuretics
Answer: B) Non-selective Beta Blockers
Rationale: Non-selective beta-blockers (e.g., propranolol) block both beta-1 and beta-2 receptors.
Blocking beta-2 receptors in the lungs can cause bronchospasm, which is dangerous for a patient
with asthma.
Q14: A patient with HFrEF (Heart Failure with reduced Ejection Fraction) is prescribed
sacubitril/valsartan (Entresto). What is a serious, potentially life-threatening adverse effect that the
nurse must monitor for?
A) Dry cough
B) Angioedema
C) Hypotension
D) Hyperkalemia
Answer: B) Angioedema
Rationale: Sacubitril/valsartan is an ARNI. A rare but severe adverse effect is angioedema, which is
swelling of the lips, tongue, and airway. This is related to bradykinin accumulation.
Q15: A patient presents with symptoms of left-sided heart failure. Which of the following findings is
most consistent with this condition?
A) Peripheral edema and jugular venous distention
B) Crackles (rales) in the lungs and dyspnea
C) Hepatomegaly and ascites
D) Hypotension and tachycardia
Answer: B) Crackles (rales) in the lungs and dyspnea
Rationale: Left-sided heart failure leads to a backup of blood into the pulmonary circulation, causing
pulmonary congestion. This manifests as symptoms like crackles, dyspnea, and orthopnea.
Q16: A patient with a diagnosis of heart failure has an ejection fraction of 50%. This finding is most
consistent with:
A) Systolic heart failure (HFrEF)
B) Diastolic heart failure (HFpEF)
C) A normal ejection fraction
D) Hypertrophic cardiomyopathy
Answer: B) Diastolic heart failure (HFpEF)
Rationale: Heart failure with preserved ejection fraction (HFpEF), also known as diastolic heart
failure, occurs when the left ventricle cannot fill properly. An EF of 50% is considered preserved.
Q17: A patient on a new ACE inhibitor for hypertension develops a persistent, dry, hacking cough.
The most likely cause of this side effect is:
A) Bronchospasm from beta-2 receptor blockade.
B) Accumulation of bradykinin in the lungs.
WGU D027 OA Exam Advanced Pathopharmacological
Foundations 200 Tested Questions (Latest ) and
Verified Rationalized Answers, 100% Guarantee Pass
Domain 1: Foundations of Pathophysiology & Cellular Function
Q1: A patient with chronic GERD develops Barrett's esophagus, where the normal squamous
epithelium is replaced by columnar epithelium with goblet cells. This cellular change is best
described as: A) Dysplasia
B) Hyperplasia
C) Metaplasia
D) Anaplasia
Answer: C) Metaplasia
Rationale: Metaplasia is the reversible replacement of one differentiated cell type with another in
response to chronic irritation, which is a protective mechanism. Barrett's esophagus is a classic
example of this adaptation.
Q2: A patient with chronic hypertension develops left ventricular wall thickening without an increase
in chamber size. This adaptation is best described as:
A) Hyperplasia
B) Hypertrophy
C) Atrophy
D) Metaplasia
Answer: B) Hypertrophy
Rationale: Hypertrophy is an increase in cell size, leading to an increase in tissue mass. Cardiac
myocytes are permanent cells that cannot divide, so they respond to increased workload (pressure
overload) by increasing in size.
Q3: A patient with a BRCA1 gene mutation has a significantly increased risk for breast and ovarian
cancer. This mutation affects a gene that is primarily responsible for:
A) Regulating cell cycle checkpoints and DNA repair
B) Controlling growth factor receptor signaling
C) Promoting apoptosis in damaged cells
D) Enhancing cell adhesion
Answer: A) Regulating cell cycle checkpoints and DNA repair
Rationale: BRCA1 and BRCA2 are tumor suppressor genes that produce proteins involved in
repairing damaged DNA. When these genes are mutated, DNA damage can accumulate, leading to
an increased risk of cancer.
Q4: Reperfusion injury following a myocardial infarction is primarily caused by: A)
A complete lack of oxygen delivery to the cardiac tissue.
B) Oxidative stress from the generation of reactive oxygen species (ROS) upon oxygen
reintroduction.
C) Mechanical damage from the pressure of reperfusion.
D) Activation of the complement system only.
, WGU D027
Answer: B) Oxidative stress from the generation of reactive oxygen species (ROS) upon oxygen
reintroduction.
Rationale: When oxygen is reintroduced to ischemic tissue, it triggers a massive generation of ROS,
which cause further cellular damage beyond the initial ischemic insult.
Q5: A patient with sickle cell trait goes on a high-altitude mountain climb and develops a splenic
infarction. The underlying mechanism is:
A) Increased oxygen saturation causing increased RBC proliferation.
B) Decreased oxygen tension causing hemoglobin S to polymerize, leading to RBC sickling.
C) Increased carbon dioxide leading to respiratory alkalosis.
D) Decreased blood viscosity causing vascular stasis.
Answer: B) Decreased oxygen tension causing hemoglobin S to polymerize, leading to RBC sickling.
Rationale: Hypoxia at high altitude causes deoxygenation of hemoglobin S, leading to polymerization
and sickling of red blood cells. These rigid, sickled cells cause vaso-occlusion and infarction.
Q6: A patient with chronic alcoholism develops hepatic steatosis (fatty liver). The primary
mechanism involves:
A) Increased fatty acid oxidation in hepatocytes.
B) Decreased lipoprotein synthesis and export, and increased lipogenesis.
C) Decreased caloric intake leading to protein malnutrition.
D) Increased bile acid synthesis.
Answer: B) Decreased lipoprotein synthesis and export, and increased lipogenesis.
Rationale: Alcohol metabolism generates excess NADH, which promotes lipogenesis and inhibits
fatty acid oxidation. It also impairs apolipoprotein synthesis, reducing VLDL export and leading to fat
accumulation.
Domain 2: Pharmacology Foundations
Q7: A patient is prescribed a drug that undergoes significant first-pass metabolism. To ensure
adequate bioavailability, the prescriber should: A) Administer the drug intravenously.
B) Increase the oral dose.
C) Administer the drug with food.
D) Use a topical formulation.
Answer: A) Administer the drug intravenously.
Rationale: The first-pass effect is the metabolism of a drug by the liver before it reaches systemic
circulation. Administering the drug intravenously bypasses the first-pass effect, delivering 100% of
the drug to the systemic circulation.
Q8: A patient is started on a medication that inhibits the CYP3A4 enzyme system. This will most likely
result in:
A) Decreased levels of drugs metabolized by CYP3A4.
B) Increased levels of drugs metabolized by CYP3A4.
C) No change in levels of drugs metabolized by CYP3A4.
D) Increased renal excretion of drugs metabolized by CYP3A4.
Answer: B) Increased levels of drugs metabolized by CYP3A4.
, WGU D027
Rationale: CYP450 enzymes are responsible for metabolizing many drugs. If a drug inhibits CYP3A4, it
will slow the metabolism of other drugs that are substrates for this enzyme, leading to increased
serum levels and a higher risk of toxicity.
Q9: A patient with a genetic variant in CYP2D6 is prescribed codeine for pain. The patient reports no
relief. This is most likely due to the patient being a: A) Poor metabolizer of codeine.
B) Rapid metabolizer of codeine.
C) Poor metabolizer of morphine.
D) Rapid metabolizer of morphine.
Answer: A) Poor metabolizer of codeine.
Rationale: Codeine is a prodrug that requires metabolism by the CYP2D6 enzyme into its active form,
morphine. A patient who is a poor metabolizer will not convert codeine effectively, resulting in
minimal analgesic effect.
Q10: Which of the following is the best measure of a drug's safety margin?
A) Potency
B) Efficacy
C) Therapeutic Index
D) Half-life
Answer: C) Therapeutic Index
Rationale: The therapeutic index (TI) is the ratio of the toxic dose to the therapeutic dose
(TD50/ED50). A high TI indicates a wide margin of safety, while a low TI indicates a narrow margin
where the drug can easily become toxic.
Q11: A patient is prescribed a drug that acts as a full agonist at the mu-opioid receptor. This means
the drug:
A) Binds to the receptor and produces a maximal response.
B) Binds to the receptor and produces a minimal response.
C) Binds to the receptor and blocks the response.
D) Binds to a different receptor entirely.
Answer: A) Binds to the receptor and produces a maximal response.
Rationale: An agonist is a drug that binds to a receptor and activates it. A full agonist produces a
maximal response, while a partial agonist produces a submaximal response. An antagonist blocks the
receptor without activating it.
Q12: The Beers Criteria is primarily used in clinical practice to: A)
Identify drugs that are safe for use in pregnant women.
B) Identify potentially inappropriate medications for older adults.
C) Determine the correct dosage for pediatric patients.
D) Monitor for drug interactions in patients with renal failure.
Answer: B) Identify potentially inappropriate medications for older adults.
Rationale: The Beers Criteria are a list of medications that are generally considered potentially
inappropriate for use in older adults due to a high risk of adverse effects or a lack of efficacy.
, WGU D027
Domain 3: Cardiovascular & Respiratory Systems
Q13: A 68-year-old patient with a history of severe asthma and chronic heart failure requires
treatment for tachycardia. Which classification of cardiovascular drug is strictly contraindicated in
this patient?
A) Cardioselective Beta-1 Blockers
B) Non-selective Beta Blockers
C) Angiotensin-Converting Enzyme (ACE) Inhibitors
D) Loop Diuretics
Answer: B) Non-selective Beta Blockers
Rationale: Non-selective beta-blockers (e.g., propranolol) block both beta-1 and beta-2 receptors.
Blocking beta-2 receptors in the lungs can cause bronchospasm, which is dangerous for a patient
with asthma.
Q14: A patient with HFrEF (Heart Failure with reduced Ejection Fraction) is prescribed
sacubitril/valsartan (Entresto). What is a serious, potentially life-threatening adverse effect that the
nurse must monitor for?
A) Dry cough
B) Angioedema
C) Hypotension
D) Hyperkalemia
Answer: B) Angioedema
Rationale: Sacubitril/valsartan is an ARNI. A rare but severe adverse effect is angioedema, which is
swelling of the lips, tongue, and airway. This is related to bradykinin accumulation.
Q15: A patient presents with symptoms of left-sided heart failure. Which of the following findings is
most consistent with this condition?
A) Peripheral edema and jugular venous distention
B) Crackles (rales) in the lungs and dyspnea
C) Hepatomegaly and ascites
D) Hypotension and tachycardia
Answer: B) Crackles (rales) in the lungs and dyspnea
Rationale: Left-sided heart failure leads to a backup of blood into the pulmonary circulation, causing
pulmonary congestion. This manifests as symptoms like crackles, dyspnea, and orthopnea.
Q16: A patient with a diagnosis of heart failure has an ejection fraction of 50%. This finding is most
consistent with:
A) Systolic heart failure (HFrEF)
B) Diastolic heart failure (HFpEF)
C) A normal ejection fraction
D) Hypertrophic cardiomyopathy
Answer: B) Diastolic heart failure (HFpEF)
Rationale: Heart failure with preserved ejection fraction (HFpEF), also known as diastolic heart
failure, occurs when the left ventricle cannot fill properly. An EF of 50% is considered preserved.
Q17: A patient on a new ACE inhibitor for hypertension develops a persistent, dry, hacking cough.
The most likely cause of this side effect is:
A) Bronchospasm from beta-2 receptor blockade.
B) Accumulation of bradykinin in the lungs.
